Literature DB >> 12626451

Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.

Raymond M Duro1, Dale Netski, Peter Thorkildson, Thomas R Kozel.   

Abstract

Incubation of encapsulated cryptococci with monoclonal antibodies (MAbs) specific for glucuronoxylomannan (GXM), the major capsular polysaccharide of Cryptococcus neoformans, produces two distinct capsular quellung-type reactions termed rim and puffy. The type of capsular reaction that occurs is determined by the epitope specificity of the MAb and the serotype of the yeast cell. Several biological activities, including opsonic activity, complement activation, and protective efficacy, are associated with the type of capsular reaction produced by a MAb. The goal of this study was to examine the reactivities of two families of anti-GXM MAbs with serotype A and D capsular polysaccharides in several immunochemical assays, including agglutination, immunofluorescence, quantitative precipitation, and enzyme-linked immunosorbent assay, in an effort to identify serological assays that are predictive of the capsular quellung reaction. The results showed that the type of capsular reaction (rim versus puffy) is a qualitative assessment of antibody-capsule interaction that cannot be predicted on the basis of a serological assay. The results further showed that antibody reactivity demonstrated in one serological assay is not necessarily predictive of results in another assay, particularly in cases where one assay examines antibody-capsule interactions, e.g., agglutination, and another assay examines interaction of antibody with soluble GXM. Taken together, the results suggest caution in interpretation of immunochemical assays for anti-GXM antibodies and recommend the use of multiple assays formats when studying anticryptococcal antibodies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12626451      PMCID: PMC150530          DOI: 10.1128/cdli.10.2.252-258.2003

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  21 in total

1.  Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.

Authors:  T R Kozel; B C deJong; M M Grinsell; R S MacGill; K K Wall
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

2.  Biological correlates of capsular (quellung) reactions of Cryptococcus neoformans.

Authors:  T C MacGill; R S MacGill; A Casadevall; T R Kozel
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

3.  Serologic grouping of Cryptococcus neoformans.

Authors:  D E Wilson; J E Bennett; J W Bailey
Journal:  Proc Soc Exp Biol Med       Date:  1968-03

4.  Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity.

Authors:  Dale Netski; Thomas R Kozel
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

5.  Cryptococcus neoformans chemotyping by quantitative analysis of 1H nuclear magnetic resonance spectra of glucuronoxylomannans with a computer-simulated artificial neural network.

Authors:  R Cherniak; H Valafar; L C Morris; F Valafar
Journal:  Clin Diagn Lab Immunol       Date:  1998-03

6.  Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody.

Authors:  F Dromer; J Charreire; A Contrepois; C Carbon; P Yeni
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

7.  Class-specific antibody response to group B Neisseria meningitidis capsular polysaccharide: use of polylysine precoating in an enzyme-linked immunosorbent assay.

Authors:  M Leinonen; C E Frasch
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

8.  Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide.

Authors:  D L Granger; J R Perfect; D T Durack
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

9.  Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody.

Authors:  T R Kozel; J L Follette
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

Review 10.  Capsular polysaccharides of Cryptococcus neoformans.

Authors:  A K Bhattacharjee; J E Bennett; C P Glaudemans
Journal:  Rev Infect Dis       Date:  1984 Sep-Oct
View more
  4 in total

1.  Differential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans.

Authors:  Marcellene A Gates; Thomas R Kozel
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

2.  Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences.

Authors:  Susana Frases; Leonardo Nimrichter; Nathan B Viana; Antonio Nakouzi; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2007-12-21

3.  Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans.

Authors:  Suzanne Brandt; Peter Thorkildson; Thomas R Kozel
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

4.  Efficacy of opsonic and nonopsonic serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibodies against intranasal challenge with Streptococcus pneumoniae in mice.

Authors:  Haijun Tian; Sarah Weber; Peter Thorkildson; Thomas R Kozel; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2009-01-21       Impact factor: 3.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.